The application belongs to the technical field of
biological materials, and particularly relates to an
enzyme response in-situ self-assembled
peptide and anti-tumor application thereof. An
amino acid sequence of the self-assembled
peptide PSK is shown in SEQ ID NO. 1. The self-assembled
peptide PSK of the application firstly combines a PD-L1 blocking peptide with a tumor
cell surface PD-L1, effectively internalizes the PSK peptide into the tumor
cell through
intracellular endocytosis, hydrolyzes in a
lysosome through Legumain response bond, triggers self-assembled module
assembly to form a beta-folded nanofilament structure, further triggers
lysosome membrane permeability change, escapes from the
lysosome, releases KLA to destroy mitochondria and induce
tumor cell apoptosis. At the same time, the PD-L1
binding peptide is endocytosed into the lysosome, releases
immunosuppression, combines with ICD induced by mitochondrial damage, enhances the killing effect of immune cells on
tumor cells in the
tumor microenvironment, effectively improves the selectivity and anti-tumor
efficacy of the polypeptide, and has good
biological safety.